Gossamer Bio's future hangs on FDA meeting after drug trial failure

Gossamer Bio is facing a critical period after its lead drug, seralutinib, failed a key clinical trial. The company's stock has dropped sharply this year, losing about 86% of its value. Investors now await an upcoming meeting with the U.S. Food and Drug Administration (FDA) in June to determine the drug's future.

The setback came in February when seralutinib missed its primary goal in the Phase 3 PROSERA trial. The study aimed to improve patients' 6-minute walk distance by at least 13.3 metres, but results fell short, with a p-value of 0.0320. Despite this, the drug showed some benefit in high-risk patients and those with connective tissue disease-associated pulmonary arterial hypertension (CTD-PAH).

Since the trial failure, analyst sentiment has split. Two firms now recommend selling the stock, while four still rate it a 'buy.' Cantor Fitzgerald recently downgraded its rating from 'Overweight' to 'Neutral.' Price targets vary widely, from as low as $0.30 to as high as $15.00, with an average of $5.43. The company's market value has shrunk to around $99 million, with shares last trading at roughly $0.42. Major financial institutions, including Barclays and Wedbush, had already cut their forecasts in late February. Gossamer Bio will report its next quarterly results on May 12, but the focus remains on the FDA's response. Concrete outcomes from the June meeting are expected by July. The discussion will decide whether seralutinib can still pursue regulatory approval or if the entire development programme will stall.

The FDA's decision in June will shape Gossamer Bio's next steps. If seralutinib cannot advance, the company may need to reassess its pipeline. For now, investors and analysts are watching closely as the stock hovers near historic lows.